Vaccine developers move to stay ahead of Covid-19 variants
Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.
Comirnaty is the real deal in the real world
Data from Israel’s real-world experience with Pfizer/Biontech’s Covid-19 vaccine should silence any doubters.
J&J’s Covid-19 vaccine set to become third to US
FDA briefing documents show intriguing findings on asymptomatic prevention, though these are based on small numbers.
Medtech
Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Onduo takes its time
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
Company Events
Go or no go? A delayed decision on Evrenzo
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Biocryst looks to raise the profile of its factor D inhibitor
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
Novartis’s canakinumab cancer test approaches
Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?
Interviews
A Spac makes it happen for 4D Pharma
The boom in blank-cheque companies could offer small UK developers a new route to a US stock market listing.
Onduo takes its time
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
Can we freeze them? Yes we can, says Nkarta
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.